

Pannie (Panayiota) Trifillis, PhD, ([LinkedIn](#))

Vice President and Head of Global Scientific Affairs,
Global Medical Affairs at PTC Therapeutics, Inc.

I am passionate about discovering, developing and commercializing innovative therapies for rare genetic diseases with a high unmet medical need, and providing access to treatment for every patient in need.

I have been dedicated to this mission over the past 22 years. As the first scientist to join PTC



Therapeutics, Inc.'s founding team, I have been fortunate to have my contributions evolve to serve the needs of the company's growth milestones. I have been trusted to serve in diverse key functions in Research & Development, Strategic Alliance Management and Global Medical Affairs. My proudest contributions were shepherding a

concept idea and taking an active role with the team to transform it into approved drug products for two rare genetic diseases, Duchenne Muscular Dystrophy and Spinal Muscular Atrophy. Standing on the NASDAQ exchange floor witnessing the team's commitment over 15 years, culminating in PTC's IPO in 2013, was a humbling moment; and a reminder then and always that the work of having our drugs approved and made accessible globally to all patients in need remains the challenge to embrace.

As the first scientist at PTC, I initiated the program that led to the discovery and development of Translarna™, the first approved, disease-modifying treatment for nonsense mutation Duchenne Muscular Dystrophy (DMD), a fatal, progressive, rare genetic disease. I subsequently led multiple drug discovery initiatives in diverse therapeutic areas beyond genetic disorders including virology and oncology and collaborated with the Korean Research Institute of Bioscience and Biotechnology securing \$768,000 in grant funding to PTC.

In 2006 I created aperture to market for the company by establishing and leading Alliance Management and executing on collaborative partnerships in diverse therapeutic areas including genetic disorders, oncology, central nervous system, cardiovascular and antibacterial diseases while working with partners in large pharma, biotech and non-profit organizations. Through these strategic joint discovery and development alliances with key partners, I delivered in excess of \$140M in revenues for PTC over 8 years. But more importantly in 2020, one of these strategic alliances between PTC, the SMA Foundation and Roche delivered Evrysdi™, a best-in-class oral treatment

for patients with Spinal Muscular Atrophy, the second rare disease drug that we have developed at PTC.

As the company looked to increase global awareness among physicians and patient advocacy organizations in 2014, I shepherded a global outreach and advocacy campaign that led to the successful marketing authorization of Translarna™ by the European Medicines Agency in August of that year. This landmark approval has granted access to this breakthrough personalized medicine to patients in the European economic area. Currently, patients in Europe, the Middle East, Asia, Latin America and North America are receiving Translarna™.

As of 2018, I serve as Vice President in Global Medical Affairs and the Head of Global Scientific Affairs at PTC, responsible for the Publications, Medical Communications, Medical Information and Medical Education & Training functions and teams globally. In this role, I support all of PTC's commercial products including Translarna™ and Emflaza™ for DMD globally and in Latin America, Tegsedi for hereditary transthyretin-mediated amyloidosis and Waylivra™ for Familial Chilomicronemia Syndrome. Additionally, I support PTC's products that are in development including Upstaza™ for Aromatic L-Amino Acid Decarboxylase Deficiency.

As part of my volunteer work, I serve as the Vice President and Secretary of the Association of Greek American Professional Women (AGAPW), a charitable and educational organization established in New York City that seeks to expand career opportunities and promote community and leadership-building among Greek-American professional women by forging collaborations among ourselves and establishing partnerships with other organizations. I also chair AGAPW's Excellence Tuition Scholarship Committee in STEM.

Additionally, I serve as a mentor for AllilonNet, a non-profit organization of Greeks and friends of Greece with the goal to facilitate communication, networking, exchange of useful information and ideas, promoting a spirit of cooperation and solidarity in the fields of studies, career and entrepreneurship.

I hold a PhD in Molecular Biology and Human Genetics from the University of Pennsylvania. I am a Fulbright Scholar, an author of a plethora of scientific publications, a patent holder and an established speaker in the global arena. I am fluent in English and Greek. I was born in Famagusta Cyprus and now live in NJ with my husband and two adult children.